About the Company
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ABCL News
AbCellera Biologics Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Should You Invest in AbCellera Biologics Inc (ABCL) Now?
Booth Andrew, the Chief Financial Officer of AbCellera Biologics Inc, purchase 14,500 shares at $6.85 during a trade that took place back on May 26 ’23, which means that Booth Andrew is holding ...
AbCellera Biologics (NASDAQ: ABCL)
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies ...
AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript
So maybe just first emphasizing as I did in my prepared remarks that we believe advancing internal portfolio is going to be the biggest value driver in the long run for AbCellera. Now our focus is ...
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across ...
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates ...
AbCellera Biologics Inc Ordinary Shares 8QQ
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
AbCellera Biologics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Abcellera Biologics Inc (ABCL)
VANCOUVER – AbCellera (NASDAQ:ABCL) announced today that Peter Thiel, a prominent technology investor and entrepreneur, has decided to step down from the company's Board of ...
Abcellera Biologics Inc (ABCL)
AbCellera (ABCL) reported Q1 EPS of $0.54, $0.24 better than the analyst estimate of $0.30. Revenue for the quarter came in at $317 million versus the consensus estimate of $179.95 ...
Loading the latest forecasts...